Literature DB >> 7779718

Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions.

P G Natali1, M R Nicotra, F Di Filippo, A Bigotti.   

Abstract

In vitro studies have demonstrated that fibronectin (FN) can deliver a mitogenic signal to quiescent human melanoma cells and that the alpha 5/beta 1-integrin receptor mediates this stimulus. In view of this finding we have analysed the in vivo expression of FN, and of ED-A and ED-B FN isoforms, in benign and malignant lesions of melanocyte origin. In the same specimens the expression of fibronectin integrin receptors was evaluated. The results demonstrate that, while detection of FN does not correlate with transformation and tumour progression, the expression of the two isoforms is associated with transformation and that only the ED-A variant is found in metastases. Integrin phenotyping disclosed that alpha 3/beta 1 expression is associated with tumour progression, alpha v/beta 3 is a marker of transformation, alpha 4 is rarely expressed and alpha 5 is expressed by about 50% and 30% of the primary and metastatic lesions respectively. Taken together, the results of this study demonstrate that transformation and tumour progression of the melanocyte lineage are associated with modulation of expression of FN isoforms and FN integrin receptors. Furthermore, the expression of alpha 5-integrin in a considerable percentage of primary and metastatic lesions indicates that FN may deliver a proliferative stimulus to melanoma cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779718      PMCID: PMC2033819          DOI: 10.1038/bjc.1995.240

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Interaction of plasma membrane fibronectin receptor with talin--a transmembrane linkage.

Authors:  A Horwitz; K Duggan; C Buck; M C Beckerle; K Burridge
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

2.  The biologic forms of malignant melanoma.

Authors:  W H Clark; D E Elder; M Van Horn
Journal:  Hum Pathol       Date:  1986-05       Impact factor: 3.466

3.  Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocytic origin.

Authors:  P G Natali; M R Nicotra; M Bellocci; R Cavaliere; A Bigotti
Journal:  Int J Cancer       Date:  1985-04-15       Impact factor: 7.396

4.  How does the extracellular matrix direct gene expression?

Authors:  M J Bissell; H G Hall; G Parry
Journal:  J Theor Biol       Date:  1982-11-07       Impact factor: 2.691

5.  Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

6.  Characteristics of cultured human melanocytes isolated from different stages of tumor progression.

Authors:  M Herlyn; J Thurin; G Balaban; J L Bennicelli; D Herlyn; D E Elder; E Bondi; D Guerry; P Nowell; W H Clark
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

7.  Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation.

Authors:  F Qian; D L Vaux; I L Weissman
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

8.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells.

Authors:  M J Humphries; K Olden; K M Yamada
Journal:  Science       Date:  1986-07-25       Impact factor: 47.728

9.  An antibody to a receptor for fibronectin and laminin perturbs cranial neural crest development in vivo.

Authors:  M Bronner-Fraser
Journal:  Dev Biol       Date:  1986-10       Impact factor: 3.582

10.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.

Authors:  L Borsi; B Carnemolla; P Castellani; C Rosellini; D Vecchio; G Allemanni; S E Chang; J Taylor-Papadimitriou; H Pande; L Zardi
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  11 in total

1.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Authors:  M Y Hsu; D T Shih; F E Meier; P Van Belle; J Y Hsu; D E Elder; C A Buck; M Herlyn
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

2.  Human melanoma progression in skin reconstructs : biological significance of bFGF.

Authors:  F Meier; M Nesbit; M Y Hsu; B Martin; P Van Belle; D E Elder; G Schaumburg-Lever; C Garbe; T M Walz; P Donatien; T M Crombleholme; M Herlyn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

4.  Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation.

Authors:  Jodi A McKenzie; Tong Liu; Agnessa G Goodson; Douglas Grossman
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

5.  Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin α5β1.

Authors:  Rika Tanaka; Yutaka Seki; Yohei Saito; Sadahiro Kamiya; Motomichi Fujita; Hiroaki Okutsu; Takuya Iyoda; Tatsuya Takai; Toshiyuki Owaki; Hirofumi Yajima; Junichi Taira; Ryo Hayashi; Hiroaki Kodama; Takuya Matsunaga; Fumio Fukai
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

6.  The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk.

Authors:  E Arpaia; H Blaser; M Quintela-Fandino; G Duncan; H S Leong; A Ablack; S C Nambiar; E F Lind; J Silvester; C K Fleming; A Rufini; M W Tusche; A Brüstle; P S Ohashi; J D Lewis; T W Mak
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

7.  The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma.

Authors:  Uwe Trefzer; Yingwen Chen; Gunda Herberth; Maja Ann Hofmann; Felix Kiecker; Yajun Guo; Wolfram Sterry
Journal:  BMC Cancer       Date:  2006-01-11       Impact factor: 4.430

8.  Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Authors:  C Haglund; S Ylätupa; P Mertaniemi; P Partanen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody.

Authors:  T Saga; H Sakahara; Z Yao; Y Nakamoto; N Sato; N Hattori; M Zhang; S Zhao; T Aoki; S Miyatake; Y Namba; J Konishi
Journal:  Jpn J Cancer Res       Date:  1997-12

10.  Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B+ by cancer cells and extra domain A+ by stromal cells.

Authors:  E Matsumoto; T Yoshida; Y Kawarada; T Sakakura
Journal:  Jpn J Cancer Res       Date:  1999-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.